Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells

Oncology Reports

Volumn 29, Issue 5, 2013, Pages 1975-1982

  Li, Xiao You ^a   Wu, Jian Zhong ^a   Cao, Hai Xia ^a   Ma, Rong ^a   Wu, Jian Qiu ^a   Zhong, Yue Jiao ^a   Feng, Ji Feng ^a  

^a JIANGSU CANCER HOSPITAL   (China)

Author keywords

5 aza 2 deoxycytidine; Epidermal growth factor receptor; Gefitinib; Methylation; Non small cell lung cancer; Tyrosine kinase inhibitor

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MESSENGER RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL COUNT; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA METHYLATION; DRUG POTENTIATION; EGFR GENE; FLOW CYTOMETRY; GENE; GENE MUTATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AZACITIDINE; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; CPG ISLANDS; DNA METHYLATION; HUMANS; LUNG NEOPLASMS; MUTATION; PROMOTER REGIONS, GENETIC; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84876231994     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2298     Document Type: Article

References (36)

1. Ahmed SM and Salgia R: Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology 11: 687-692, 2006. (Pubitemid 44581431)
2. Hynes NE and Lane HA: ERBB Receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354, 2005. (Pubitemid 40637826)
3. Yarden Y and Sliwkowski MX: Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
4. Citri A, Skaria KB and Yarden Y: The deaf and the dumb: The biology of ErbB-2 and ErbB-3. Exp Cell Res 284: 54-65, 2003. (Pubitemid 36342255)
5. Baselga J: Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7: 2-8, 2002.
6. Cappuzzo F, Finocchiaro G, Metro G, Bartolini S, Magrini E, Cancellieri A, Trisolini R, Castaldini L, Tallini G and Crino L: Clinical experience with gefitinib: An update. Crit Rev Oncol Hematol 24:31-45, 2006.
7. Haber DA, Bell DW, Sordella R, et al: Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harb Symp Quant Biol 70: 419-426, 2005. (Pubitemid 44124897)
8. Janne PA and Johnson BE: Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 12: 4416-4420, 2006.
9. Esteller M: Cancer epigenomics: DNA methylation and histone-modification maps. Nat Rev Gene 8: 286-298, 2007.
10. Sharma S, Kelly TK and Jones PA: Epigenetics in Cancer. Carcinogenesis 31: 27-36, 2010.
11. Silva M, Azenha D, Pereira C, et al: Gastric carcionoma and chronic gastritis: epigenetic regulation of CDH1 (E-cadherin), CDKN2A (p16INK4A), PTGS2 (COX-2) and EGFR genes through methylation. Acta Med Port 23: 5-14, 2010 (In Portuguese).
12. Wang Z, Xu J, Geng X and Zhang W: Analysis of DNA methylation status of the promoter of human telomerase reverse transciptase in gastric carcinogenesis. Arch Med Res 41: 1-6, 2010.
13. Taron M, Rosell R, Felip E, et al: BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 13: 2443-2449, 2004. (Pubitemid 39377848)
14. Grivaux M, Zureik M, Marsal L, et al: Five-year survival for lung cancer patients managed in general hospitals. Rev Mal Respir 28: e31-e38, 2011.
15. Gadgeel SM, Ali S, Philip PA, Wozniak A and Sarkar FH: Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in non-small cell lung cancer cell lines. Cancer 115: 2165-2176, 2009.
16. Vucic EA, Brown CJ and Lam WL: Epigenetics of cancer progression. Pharmacogenomics 9: 215-234, 2008. (Pubitemid 351575091)
17. Duffy MJ, Napieralski R, Martens JW, et al: Methylated genes as new cancer biomarkers. Eur J Cancer 45: 335-346, 2009.
18. Kim YT, Park SJ, Lee SH, et al: Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung. J Thorac Cardiovasc Surg 130: 1378, 2005.
19. Safar AM, Spencer H III, Su X, et al: Methylation profiling of archived non-small cell lung cancer: a promising prognostic system. Clin Cancer Res 11: 4400-4405, 2005. (Pubitemid 40825630)
20. Plimack ER, Stewart DJ and Issa JP: Combining epigenetic and cytotoxic therapy in the treatment of solid tumors. J Clin Oncol 25: 4519-4521, 2007. (Pubitemid 350035304)
21. Daskalakis M, Blaqitko-Dorfs N and Hackanson B: Decitabine. Recent Results Cancer Res 184: 131-157, 2010.
22. Chai G, Li L, Zhou W, et al: HDAC inhibitors act with 5-aza-2′-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells. PLoS One 3: e2445, 2008.
23. Montero AJ, Díaz-Montero CM, Mao L, et al: Epigenetic inactivation of EGFR by CpG island hypermethylation in cancer. Cancer Biol Ther 5: 1494-1501, 2006.
24. Majumdar AP, Kodali U and Jaszewski R: Chemopreventive role of folic acid in colorectal cancer. Front Biosci 9: 2725-2732, 2004.
25. Nagothu KK, Rishi AK, Jaszewski R, Kucuk O and Majumdar AP: Folic acid-mediated inhibition of serum-induced activation of EGFR promoter in colon cancer cells. Am J Physiol Gastrointest Liver Physiol 287: G541-G546, 2004. (Pubitemid 39096619)
26. Momparler RL and Ayoub J: Potential of 5-aza-2′-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. Lung Cancer 34 (Suppl 4): S111-S115, 2001.
27. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004. (Pubitemid 38637993)
28. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004. (Pubitemid 38720929)
29. Sharma SV, Bell DW, Settleman J and Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181, 2007.
30. Tsao M-S, Sakurada A, Cutz J-C, et al: Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353: 133-144, 2005. (Pubitemid 41058345)
31. Yun CH, Menqwasser KE, Toms AV, et al: The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 105: 2070-2075, 2008. (Pubitemid 351439466)
32. Pao W, Miller VA, Politi KA, et al: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73, 2005.
33. Kosaka T, Yatabe Y, Endoh H, et al: Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12: 5764-5769, 2006. (Pubitemid 44629607)
34. Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043, 2007. (Pubitemid 46799492)
35. Guo A, Villen J, Kornhauser J, et al: Signaling networks assembled by oncogenic EGFR and c-met. Proc Natl Acad Sci USA 105: 692-697, 2008. (Pubitemid 351171770)
36. Watanabe K, Emoto N, Hamano E, et al: Genome structure-based screening identified epigenetically silenced microRNA associated with invasiveness in non-small-cell lung cancer. Int J Cancer 130: 2580-2590, 2012.